Type 1 diabetes: Translating mechanistic observations into effective clinical outcomes

Nature Reviews Immunology

Volumn 13, Issue 4, 2013, Pages 243-256

  Herold, Kevan C ^a   Vignali, Dario A A ^b   Cooke, Anne ^c   Bluestone, Jeffrey A ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ADAPTIVE IMMUNITY; ANIMALS; CHILD; DIABETES MELLITUS, TYPE 1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MODELS, IMMUNOLOGICAL;

EID: 84875432419     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3422     Document Type: Review

References (180)

1. Eisenbarth, G. S. Type I diabetes mellitus. A chronic autoimmune disease. N. Engl. J. Med. 314, 1360-1368 (1986). (Pubitemid 16122469)
2. Bottazzo, G. F., Florin-Christensen, A. & Doniach, D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2, 1279-1283 (1974).
3. Sibley, R. K., Sutherland, D. E., Goetz, F. & Michael, A. F. Recurrent diabetes mellitus in the pancreas iso-and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab. Invest. 53, 132-144 (1985). (Pubitemid 15049005)
4. Eisenbarth, G. S. et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res. 2, 271-276 (1985). (Pubitemid 16213226)
5. Stiller, C. R. et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223, 1362-1367 (1984). (Pubitemid 14161003)
6. Faber, O. K. & Binder, C. Bcell function and blood glucose control in insulin dependent diabetics within the first month of insulin treatment. Diabetologia 13, 263-268 (1977). (Pubitemid 8109393)
7. Palmer, J. P., et al. Cpeptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53, 250-264 (2004). (Pubitemid 38044724)
8. Steffes, M. W. Sibley, S., Jackson, M. & Thomas, W. β-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 26, 832-836 (2003). (Pubitemid 36929351)
9. Ziegler, A. G. et al. Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children. J. Autoimmun. 37, 3-7 (2011).
10. Dunne, D. W. & Cooke, A. A worm's eye view of the immune system: consequences for evolution of human autoimmune disease. Nature Rev. Immunol. 5, 420-426 (2005). (Pubitemid 40685991)
11. Atkinson, M. A. et al. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J. Clin. Invest. 94, 2125-2129 (1994). (Pubitemid 24348254)
12. Strachan, D. P. Hay fever, hygiene, and household size. BMJ 299, 1259-1260 (1989). (Pubitemid 19280051)
13. Bach, J. F. & Chatenoud, L. The hygiene hypothesis: an explanation for the increased frequency of insulin-dependent diabetes. Cold Spring Harb. Perspect. Med. 2, a007799 (2012).
14. Cooke, A., Zaccone, P., Raine, T., Phillips, J. M. & Dunne, D. W. Infection and autoimmunity: are we winning the war, only to lose the peace? Trends Parasitol. 20, 316-321 (2004). (Pubitemid 38749074)
15. David, T., Thomas, C., Zaccone, P., Dunne, D. W. & Cooke, A. The impact of infection on the incidence of autoimmune disease. Curr. Top. Med. Chem. 4, 521-529 (2004). (Pubitemid 38832735)
16. Dotta, F. et al. Coxsackie B4 virus infection of β cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc. Natl Acad. Sci. USA 104, 5115-5120 (2007). (Pubitemid 47186185)
17. Yoon, J. W., Austin, M., Onodera, T. & Notkins, A. L. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N. Engl. J. Med. 300, 1173-1179 (1979). (Pubitemid 9191515)
18. Akatsuka, H. et al. A case of fulminant type 1 diabetes with coxsackie B4 virus infection diagnosed by elevated serum levels of neutralizing antibody. Diabetes Res. Clin. Pract. 84, e50-e52 (2009).
19. Berg, A. K., Korsgren, O. & Frisk, G. Induction of the chemokine interferon-γ-inducible protein10 in human pancreatic islets during enterovirus infection. Diabetologia 49, 2697-2703 (2006).
20. Christen, U., McGavern, D. B., Luster, A. D., von Herrath, M. G. & Oldstone, M. B. Among CXCR3 chemokines, IFN-γ-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-γ (CXCL9) imprints a pattern for the subsequent development of autoimmune disease. J. Immunol. 171, 6838-6845 (2003). (Pubitemid 37532119)
21. Schulte, B. M. et al. Phagocytosis of enterovirus-infected pancreatic β-cells triggers innate immune responses in human dendritic cells. Diabetes 59, 1182-1191 (2010).
22. Chung, H. et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell 149, 1578-1593 (2012).
23. Mathis, D. & Benoist, C. The influence of the microbiota on type1 diabetes: on the threshold of a leap forward in our understanding. Immunol. Rev. 245, 239-249 (2012).
24. Round, J. L. & Mazmanian, S. K. Inducible Foxp3+ regulatory Tcell development by a commensal bacterium of the intestinal microbiota. Proc. Natl Acad. Sci. USA 107, 12204-12209 (2010).
25. Giongo, A. et al. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J. 5, 82-91 (2011).
26. Perez-Cano, F. J., Dong, H. & Yaqoob, P. In vitro immunomodulatory activity of Lactobacillus fermentum CECT5716 and Lactobacillus salivarius CECT5713: two probiotic strains isolated from human breast milk. Immunobiology 215, 996-1004 (2010).
27. Lee, Y. K., Menezes, J. S., Umesaki, Y. & Mazmanian, S. K. Proinflammatory Tcell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 108 (Suppl. 1), 4615-4622 (2011).
28. Ivanov, I. I. et al. Specific microbiota direct the differentiation of IL17producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4, 337-349 (2008).
29. Geuking, M. B. et al. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity 34, 794-806 (2011).
30. Kriegel, M. A. et al. Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proc. Natl Acad. Sci. USA 108, 11548-11553 (2011).
31. Wen, L. et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 455, 1109-1113 (2008).
32. Knip, M., Virtanen, S. M. & Akerblom, H. K. Infant feeding and the risk of type 1 diabetes. Am J. Clin Nutr 91, 1506S-1513S (2010).
33. Ziegler, A. G., Schmid, S., Huber, D., Hummel, M. & Bonifacio, E. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA 290, 1721-1728 (2003). (Pubitemid 37430622)
34. Norris, J. M. et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA 290, 1713-1720 (2003). (Pubitemid 37430621)
35. Akerblom, H. K. et al. Dietary manipulation of β cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study. Diabetologia 48, 829-837 (2005). (Pubitemid 40767974)
36. Knip, M. et al. Dietary intervention in infancy and later signs of β-cell autoimmunity. N. Engl. J. Med. 363, 1900-1908 (2010).
37. Wong, F. S. et al. Investigation of the role of Bcells in type 1 diabetes in the NOD mouse. Diabetes 53, 2581-2587 (2004). (Pubitemid 39299265)
38. Fiorina, P. et al. Targeting CD22 reprograms Bcells and reverses autoimmune diabetes. Diabetes 57, 3013-3024 (2008).
39. Hu, C. Y. et al. Treatment with CD20specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117, 3857-3867 (2007).
40. Wenzlau, J. M. et al. The cation efflux transporter ZNT8 (SLC30A8) is a major autoantigen in human type 1 diabetes. Proc. Natl Acad. Sci. USA 104, 17040-17045 (2007). (Pubitemid 350210987)
41. Krishnamurthy, B. et al. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J. Clin. Invest. 116, 3258-3265 (2006). (Pubitemid 44878640)
42. Nakayama, M. et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435, 220-223 (2005). (Pubitemid 40685949)
43. Bot, A. et al. Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. J. Immunol. 167, 2950-2955 (2001). (Pubitemid 32768931)
44. von Herrath, M., Sanda, S. & Herold, K. Type 1 diabetes as a relapsing-remitting disease? Nature Rev. Immunol. 7, 988-994 (2007). (Pubitemid 350166057)
45. Yu, L. et al. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc. Natl Acad. Sci. USA 97, 1701-1706 (2000). (Pubitemid 30118506)
46. Skowera, A. et al. CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J. Clin. Invest. 118, 3390-3402 (2008).
47. Jaeckel, E., Lipes, M. A. & von Boehmer, H. Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes. Nature Immunol. 5, 1028-1035 (2004). (Pubitemid 41057722)
48. Thebault-Baumont, K. et al. Acceleration of type 1 diabetes mellitus in proinsulin 2deficient NOD mice. J. Clin. Invest. 111, 851-857 (2003). (Pubitemid 37074960)
49. Mathis, D. & Benoist, C. Back to central tolerance. Immunity 20, 509-516 (2004). (Pubitemid 38638121)
50. Anderson, M. S. et al. The cellular mechanism of AIRE control of T cell tolerance. Immunity 23, 227-239 (2005). (Pubitemid 41169291)
51. Moriyama, H. et al. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc. Natl Acad. Sci. USA 100, 10376-10381 (2003). (Pubitemid 37071886)
52. Chentoufi, A. A. & Polychronakos, C. Insulin expression levels in the thymus modulate insulin-specific autoreactive Tcell tolerance: the mechanism by which the IDDM2 locus may predispose to diabetes. Diabetes 51, 1383-1390 (2002). (Pubitemid 34826603)
53. Mohan, J. F. et al. Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes. Nature Immunol. 11, 350-354 (2010).
54. Mohan, J. F., Petzold, S. J. & Unanue, E. R. Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J. Exp. Med. 208, 2375-2383 (2011).
55. Stadinski, B., Kappler, J. & Eisenbarth, G. S. Molecular targeting of islet autoantigens. Immunity 32, 446-456 (2010).
56. Crawford, F. et al. Specificity and detection of insulin-reactive CD4+ T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse. Proc. Natl Acad. Sci. USA 108, 16729-16734 (2011).
57. Stadinski, B. D. et al. Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc. Natl Acad. Sci. USA 107, 10978-10983 (2010).
58. Menard, L. et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J. Clin. Invest. 121, 3635-3644 (2011).
59. Concannon, P., Rich, S. S. & Nepom, G. T. Genetics of type 1A diabetes. N. Engl. J. Med. 360, 1646-1654 (2009).
60. Christianson, S. W., Shultz, L. D. & Leiter, E. H. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ Tcells from diabetic versus prediabetic NOD.NON-Thy1a donors. Diabetes 42, 44-55 (1993). (Pubitemid 23013794)
61. Miller, B. J., Appel, M. C., O'Neil, J. J. & Wicker, L. S. Both the Lyt2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J. Immunol. 140, 52-58 (1988). (Pubitemid 18050680)
62. Andre, I. et al. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc. Natl Acad. Sci. USA 93, 2260-2263 (1996). (Pubitemid 26104338)
63. Katz, J. D., Wang, B., Haskins, K., Benoist, C. & Mathis, D. Following a diabetogenic T cell from genesis through pathogenesis. Cell 74, 1089-1100 (1993). (Pubitemid 23289465)
64. Verdaguer, J. et al. Acceleration of spontaneous diabetes in TCR-β-transgenic nonobese diabetic mice by β-cell cytotoxic CD8+ T cells expressing identical endogenous TCR-α chains. J. Immunol. 157, 4726-4735 (1996). (Pubitemid 126449398)
65. Lennon, G. P. et al. T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. Immunity 31, 643-653 (2009).
66. van den Elzen, P. et al. Limited clonality in autoimmunity: drivers and regulators. Autoimmun. Rev. 3, 524-529 (2004). (Pubitemid 39531245)
67. Baker, F. J., Lee, M., Chien, Y. H. & Davis, M. M. Restricted islet-cell reactive T cell repertoire of early pancreatic islet infiltrates in NOD mice. Proc. Natl Acad. Sci. USA 99, 9374-9379 (2002). (Pubitemid 34764621)
68. Codina-Busqueta, E. et al. TCR bias of in vivo expanded T cells in pancreatic islets and spleen at the onset in human type 1 diabetes. J. Immunol. 186, 3787-3797 (2011).
69. Nakayama, M. et al. Germline TRAV5D4 Tcell receptor sequence targets a primary insulin peptide of NOD mice. Diabetes 61, 857-865 (2012).
70. Arnold, P. Y., Burton, A. R. & Vignali, D. A. Diabetes incidence is unaltered in glutamate decarboxylase 65specific TCR retrogenic nonobese diabetic mice: generation by retroviral-mediated stem cell gene transfer. J. Immunol. 173, 3103-3111 (2004). (Pubitemid 39142016)
71. Holst, J. et al. Generation of Tcell receptor retrogenic mice. Nature Protoc. 1, 406-417 (2006).
72. Holst, J., Vignali, K. M., Burton, A. R. & Vignali, D. A. Rapid analysis of Tcell selection in vivo using T cell-receptor retrogenic mice. Nature Methods 3, 191-197 (2006).
73. Bettini, M. L., Bettini, M. & Vignali, D. A. Tcell receptor retrogenic mice: a rapid, flexible alternative to Tcell receptor transgenic mice. Immunology 136, 265-272 (2012).
74. Campbell-Thompson, M. et al. Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab. Res. Rev. 28, 608-617 (2012).
75. Coppieters, K. T. et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J. Exp. Med. 209, 51-60 (2012).
76. Sherr, J., Sosenko, J., Skyler, J. S. & Herold, K. C. Prevention of type 1 diabetes: the time has come. Nature Clin. Pract. Endocrinol. Metab. 4, 334-343 (2008). (Pubitemid 351733474)
77. Orban, T. et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 32, 2269-2274 (2009).
78. Krischer, J. P. et al. Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J. Clin. Endocrinol. Metab. 88, 103-108 (2003). (Pubitemid 36115150)
79. Waldmann, H. & Cobbold, S. How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annu. Rev. Immunol. 16, 619-644 (1998). (Pubitemid 28183379)
80. Fourlanos, S. et al. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 60, 1237-1245 (2011).
81. Chaillous, L. et al. Oral insulin administration and residual β-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Lancet 356, 545-549 (2000). (Pubitemid 30611859)
82. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 346, 1685-1691 (2002).
83. Skyler, J. S. et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 28, 1068-1076 (2005). (Pubitemid 40616615)
84. Ludvigsson, J. et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med. 359, 1909-1920 (2008).
85. Ludvigsson, J. et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N. Engl. J. Med. 366, 433-442 (2012).
86. Wherrett, D. K. et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 378, 319-327 (2011).
87. Gottlieb, P. A. et al. Failure to preserve β-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 33, 826-832 (2010).
88. Pescovitz, M. D. et al. Rituximab, Blymphocyte depletion, and preservation of β-cell function. N. Engl. J. Med. 361, 2143-2152 (2009).
89. Herold, K. C. et al. Increased T cell proliferative responses to islet antigens identify clinical responders to antiCD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J. Immunol. 187, 1998-2005 (2011).
90. Yu, L. et al. Rituximab selectively suppresses specific islet antibodies. Diabetes 60, 2560-2565 (2011).
91. Lenschow, D. J. et al. Differential effects of antiB71 and antiB72 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181, 1145-1155 (1995).
92. Lenschow, D. J. et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 5, 285-293 (1996). (Pubitemid 26341371)
93. Orban, T. et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378, 412-419 (2011).
94. Itoh, N. et al. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J. Clin. Invest. 92, 2313-2322 (1993). (Pubitemid 23333537)
95. Ogasawara, K. et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 20, 757-767 (2004). (Pubitemid 38757445)
96. Beilke, J. N. et al. NK cells are not required for spontaneous autoimmune diabetes in NOD mice. PLoS ONE 7, e36011 (2012).
97. Amrani, A. et al. Interleukin1 effect on glycemia in the non-obese diabetic mouse at the pre-diabetic stage. J. Endocrinol. 148, 139-148 (1996). (Pubitemid 26017042)
98. Rabinovitch, A., Baquerizo, H. & Sumoski, W. Cytotoxic effects of cytokines on islet β-cells: evidence for involvement of eicosanoids. Endocrinology 126, 67-71 (1990). (Pubitemid 20037126)
99. Thomas, H. E. et al. IL1 receptor deficiency slows progression to diabetes in the NOD mouse. Diabetes 53, 113-121 (2004). (Pubitemid 38044705)
100. Cailleau, C., Diu-Hercend, A., Ruuth, E., Westwood, R. & Carnaud, C. Treatment with neutralizing antibodies specific for IL1β prevents cyclophosphamide-induced diabetes in nonobese diabetic mice. Diabetes 46, 937-940 (1997). (Pubitemid 27220991)
101. Foulis, A. K., McGill, M. & Farquharson, M. A. Insulitis in type 1 (insulin-dependent) diabetes mellitus in man-macrophages, lymphocytes, and interferon-γ containing cells. J. Pathol. 165, 97-103 (1991).
102. Koulmanda, M. et al. Curative and β cell regenerative effects of α1antitrypsin treatment in autoimmune diabetic NOD mice. Proc. Natl Acad. Sci. USA 105, 16242-16247 (2008).
103. Schilling, E. et al. Inhibition of nicotinamide phosphoribosyltransferase modifies LPS-induced inflammatory responses of human monocytes. Innate Immun. 18, 518-530 (2012).
104. Gale, E. A., Bingley, P. J., Emmett, C. L. & Collier, T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 363, 925-931 (2004).
105. Larsen, C. M. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526 (2007). (Pubitemid 46588416)
106. Sanda, S. et al. Short-term IL1β blockade reduces monocyte CD11b integrin expression in an IL8 dependent fashion in patients with type 1 diabetes. Clin. Immunol. 136, 170-173 (2010).
107. Zanin-Zhorov, A. et al. Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling. J. Clin. Invest. 116, 2022-2032 (2006). (Pubitemid 44033326)
108. Raz, I. et al. β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358, 1749-1753 (2001). (Pubitemid 33152998)
109. Liu, W. et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 203, 1701-1711 (2006). (Pubitemid 44036276)
110. Brusko, T. M., Putnam, A. L. & Bluestone, J. A. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol. Rev. 223, 371-390 (2008). (Pubitemid 351986182)
111. Zhou, X. et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nature Immunol. 10, 1000-1007 (2009).
112. Zheng, Y. et al. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 463, 808-812 (2010).
113. Salomon, B. & Bluestone, J. A. Complexities of CD28/B7: CTLA4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19, 225-252 (2001). (Pubitemid 32368035)
114. Salomon, B. et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431-440 (2000).
115. Ablamunits, V., Henegariu, O., Preston-Hurlburt, P. & Herold, K. C. NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with antiCD3 antibody. Eur. J. Immunol. 41, 1832-1842 (2011).
116. Green, E. A., Gorelik, L., McGregor, C. M., Tran, E. H. & Flavell, R. A. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-β-TGF-β receptor interactions in type 1 diabetes. Proc. Natl Acad. Sci. USA 100, 10878-10883 (2003). (Pubitemid 37140121)
117. You, S. et al. Adaptive TGF-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of antiCD3 antibody treatment. Proc. Natl Acad. Sci. USA 104, 6335-6340 (2007). (Pubitemid 47186095)
118. Levings, M. K., Sangregorio, R. & Roncarolo, M. G. Human CD25+CD4+ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 193, 1295-1302 (2001).
119. Levings, M. K. et al. Human CD25+CD4+ T suppressor cell clones produce transforming growth factor β, but not interleukin 10, and are distinct from type 1 T regulatory cells. J. Exp. Med. 196, 1335-1346 (2002). (Pubitemid 35375552)
120. Roncarolo, M. G., Bacchetta, R., Bordignon, C., Narula, S. & Levings, M. K. Type 1 T regulatory cells. Immunol. Rev. 182, 68-79 (2001). (Pubitemid 33070208)
121. Heiber, J. F. & Geiger, T. L. Context and location dependence of adaptive Foxp3+regulatory T cell formation during immunopathological conditions. Cell. Immunol. 279, 60-65 (2012).
122. Bettini, M. et al. Cutting edge: accelerated autoimmune diabetes in the absence of LAG3. J. Immunol. 187, 3493-3498 (2011).
123. Tivol, E. A. et al. Loss of CTLA4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA4. Immunity 3, 541-547 (1995).
124. Tang, Q. et al. Distinct roles of CTLA4 and TGF-β in CD4+CD25+ regulatory T cell function. Eur. J. Immunol. 34, 2996-3005 (2004). (Pubitemid 39549379)
125. Alyanakian, M. A. et al. Transforming growth factor-β and natural killer Tcells are involved in the protective effect of a bacterial extract on type 1 diabetes. Diabetes 55, 179-185 (2006).
126. Mellor, A. L. & Munn, D. H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nature Rev. Immunol. 4, 762-774 (2004). (Pubitemid 39336293)
127. Collison, L. W. et al. IL35mediated induction of a potent regulatory T cell population. Nature Immunol. 11, 1093-1101 (2010).
128. Maier, L. M. et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin2 receptor production. PLoS Genet. 5, e1000322 (2009).
129. Ueda, H. et al. Association of the Tcell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423, 506-511 (2003). (Pubitemid 36648570)
130. Long, S. A. et al. Defects in IL2R signaling contribute to diminished maintenance of FOXP3 expression in CD4+CD25+ regulatory Tcells of type 1 diabetic subjects. Diabetes 59, 407-415 (2010).
131. Grinberg-Bleyer, Y. et al. IL2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. Exp. Med. 207, 1871-1878 (2010).
132. McClymont, S. A. et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J. Immunol. 186, 3918-3926 (2011).
133. Rabinovitch, A., Suarez-Pinzon, W. L., Shapiro, A. M., Rajotte, R. V. & Power, R. Combination therapy with sirolimus and interleukin2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 51, 638-645 (2002). (Pubitemid 34760170)
134. Simon, G. et al. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes 57, 405-414 (2008).
135. Belghith, M. et al. TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nature Med. 9, 1202-1208 (2003). (Pubitemid 37173706)
136. Esplugues, E. et al. Control of TH17 cells occurs in the small intestine. Nature 475, 514-518 (2011).
137. Waldron-Lynch, F. et al. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci. Transl. Med. 4, 118ra112 (2012).
138. Herold, K. C. et al. A single course of antiCD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in Cpeptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54, 1763-1769 (2005). (Pubitemid 40770766)
139. Herold, K. C. et al. AntiCD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692-1698 (2002). (Pubitemid 34547482)
140. Keymeulen, B. et al. Insulin needs after CD3antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352, 2598-2608 (2005). (Pubitemid 41007846)
141. Keymeulen, B. et al. Four-year metabolic outcome of a randomised controlled CD3antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual β cell mass. Diabetologia 53, 614-623 (2010).
142. Bisikirska, B., Colgan, J., Luban, J., Bluestone, J. A. & Herold, K. C. TCR stimulation with modified antiCD3 mAb expands CD8 T cell population and induces CD8CD25 TRegs. J. Clin. Invest. 115, 2904-2913 (2005). (Pubitemid 41434418)
143. Herold, K. C. et al. Activation of human T cells by FcR nonbinding antiCD3 mAb, hOKT3γ1(Ala-Ala). J. Clin. Invest. 111, 409-418 (2003). (Pubitemid 36182218)
144. Sherry, N. et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1year results from a randomised, placebo-controlled trial. Lancet 378, 487-497 (2011).
145. Herold, K. C. et al. Teplizumab treatment may improve Cpeptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 56, 391-400 (2012).
146. Long, S. A. et al. Rapamycin/IL2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes 61, 2340-2348 (2012).
147. Qin, S. et al. "Infectious" transplantation tolerance. Science 259, 974-977 (1993).
148. Ablamunits, V. et al. Synergistic reversal of type 1 diabetes in NOD mice with antiCD3 and interleukin1 blockade: evidence of improved immune regulation. Diabetes 61, 145-154 (2012).
149. Kwon, G., Corbett, J. A., Rodi, C. P., Sullivan, P. & McDaniel, M. L. Interleukin1 β-induced nitric oxide synthase expression by rat pancreatic β-cells: evidence for the involvement of nuclear factor κ B in the signaling mechanism. Endocrinology 136, 4790-4795 (1995). (Pubitemid 3002171)
150. Gysemans, C. et al. Interferon regulatory factor1 is a key transcription factor in murine β cells under immune attack. Diabetologia 52, 2374-2384 (2009).
151. Akirav, E., Kushner, J. A. & Herold, K. C. β-cell mass and type 1 diabetes: going, going, gone? Diabetes 57, 2883-2888 (2008).
152. Sherry, N. A. et al. Effects of autoimmunity and immune therapy on β-cell turnover in type 1 diabetes. Diabetes 55, 3238-3245 (2006). (Pubitemid 44923579)
153. Akirav, E. M. et al. Detection of β cell death in diabetes using differentially methylated circulating DNA. Proc. Natl Acad. Sci. USA 108, 19018-19023 (2011).
154. Talchai, C., Xuan, S., Lin, H. V., Sussel, L. & Accili, D. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell 150, 1223-1234 (2012).
155. Eizirik, D.L. & Darville, M.I. β-cell apoptosis and defense mechanisms: lessons from type 1 diabetes. Diabetes 50 (Suppl. 1), S64-69 (2001). (Pubitemid 32148222)
156. Melton, D. A. Using stem cells to study and possibly treat type 1 diabetes. Phil. Trans. R. Soc. B 366, 2307-2311 (2011).
157. Patterson, C. C., Dahlquist, G. G., Gyurus, E., Green, A. & Soltesz, G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 373, 2027-2033 (2009).
158. Riley, W. J. et al. A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes. N. Engl. J. Med. 323, 1167-1172 (1990). (Pubitemid 20347402)
159. Sabbah, E. et al. Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. J. Clin. Endocrinol. Metab. 84, 1534-1539 (1999). (Pubitemid 30644249)
160. Greenbaum, C. J. et al. Fall in Cpeptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite TrialNet data. Diabetes 61, 2066-2073 (2012).
161. Goodnow, C. C., Sprent, J., Fazekas de St Groth, B. & Vinuesa, C. G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435, 590-597 (2005).
162. Halverson, R., Torres, R. M. & Pelanda, R. Receptor editing is the main mechanism of B cell tolerance toward membrane antigens. Nature Immunol. 5, 645-650 (2004). (Pubitemid 38811890)
163. Hertz, M. & Nemazee, D. BCR ligation induces receptor editing in IgM+IgD-bone marrow B cells in vitro. Immunity 6, 429-436 (1997). (Pubitemid 27208198)
164. Bluestone, J. A. & Abbas, A. K. Natural versus adaptive regulatory T cells. Nature Rev. Immunol. 3, 253-257 (2003). (Pubitemid 37323210)
165. Harjutsalo, V., Podar, T. & Tuomilehto, J. Cumulative incidence of type 1 diabetes in 10,168 siblings of Finnish young-onset type 1 diabetic patients. Diabetes 54, 563-569 (2005).
166. Steck, A. K. & Rewers, M. J. Genetics of type 1 diabetes. Clin. Chem. 57, 176-185 (2011).
167. Redondo, M. J., Jeffrey, J., Fain, P. R., Eisenbarth, G. S. & Orban, T. Concordance for islet autoimmunity among monozygotic twins. N. Engl. J. Med. 359, 2849-2850 (2008).
168. Barrett, J. C. et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nature Genet. 41, 703-707 (2009).
169. Fernando, M. M. et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet. 4, e1000024 (2008).
170. Zhang, Z. J., Davidson, L., Eisenbarth, G. & Weiner, H. L. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl Acad. Sci. USA 88, 10252-10256 (1991). (Pubitemid 21915813)
171. Tian, J. et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nature Med. 2, 1348-1353 (1996).
172. Moran, A. et al. Interleukin1 antagonism in type 1 diabetes of recent onset: two multicenter, randomized double-masked, placebo-controlled trials. Lancet (in the press).
173. Shoda, L. K. et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23, 115-126 (2005). (Pubitemid 41169282)
174. Stoffers, D. A., Desai, B. M., DeLeon, D. D. & Simmons, R. A. Neonatal exendin4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes 52, 734-740 (2003). (Pubitemid 36323581)
175. Mestas, J. & Hughes, C. C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731-2738 (2004). (Pubitemid 38263654)
176. Steele, C. et al. Insulin secretion in type 1 diabetes. Diabetes 53, 426-433 (2004). (Pubitemid 38174559)
177. Sosenko, J. M. et al. Patterns of metabolic progression to type 1 diabetes in the diabetes prevention trial-type 1. Diabetes Care 29, 643-649 (2006). (Pubitemid 44115367)
178. Voltarelli, J. C. et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297, 1568-1576 (2007). (Pubitemid 46588370)
179. Couri, C. E. et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 301, 1573-1539 (2009).
180. Mastrandrea, L. et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 32, 1244-1249 (2009).